The Wall Street Journal in an article written by Rumman Ahmed and published in the February 8th edition, reports on the continued issues between the U.S. Food and Drug Administration and Ranbaxy Laboratories.
According to the story, the U.S. regulatory authority is accusing the drug maker of “an insufficient effort to meet manufacturing standards”.
U.S. sales, Ranbaxy’s biggest overseas markets have been depressed for more than a year because of manufacturing deficiencies at some of their plants.
This particular set of issues, based on substandard overseas manufacturing, energizes the need for material screening of products within the supply chain, from raw materials to dispensing, to properly protect consumers from fraud, adulteration, contamination and counterfeit products.
To read the entire Wall Street Journal article, visit:
http://online.wsj.com/article/SB10001424052748704533204575046671948801274.html.html.
http://online.wsj.com/article/SB10001424052748704533204575046671948801274.html.html.
To learn more about supply chain material authentication solutions, visit: http://www.xstreamsystems.net/.
Posts
No comments:
Post a Comment